As shown in Fig. 2C, the PI3K and ERK inhibitors significantly increased basal E-cadherin expression and markedly diminished, but did not completely abolish, FGF2-induced suppression of E-cadherin expression, which demonstrated the involvement of the PI3K/Akt and MAPK/ERK pathways in the FGF2-mediated down-regulation of E-cadherin expression in ovarian cancer cells. The gene discussed is FGF2; the disease is ovarian cancer.